Last reviewed · How we verify
Matched-Placebo for Primaquine
Matched-Placebo for Primaquine is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Placebo control arm in clinical trials of primaquine for malaria (likely P. vivax or P. ovale relapsing malaria).
This is a placebo control formulation matched to primaquine, an antimalarial drug that eliminates dormant liver-stage parasites and gametocytes.
This is a placebo control formulation matched to primaquine, an antimalarial drug that eliminates dormant liver-stage parasites and gametocytes. Used for Placebo control arm in clinical trials of primaquine for malaria (likely P. vivax or P. ovale relapsing malaria).
At a glance
| Generic name | Matched-Placebo for Primaquine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Matched-placebo formulations are used in clinical trials to maintain blinding while comparing the active drug (primaquine) against an inert control. Primaquine itself works by generating reactive oxygen species in parasitized cells, particularly targeting hypnozoites (dormant forms) in the liver and sexual-stage gametocytes in the blood. The matched placebo is designed to be indistinguishable from the active formulation in appearance, taste, and administration.
Approved indications
- Placebo control arm in clinical trials of primaquine for malaria (likely P. vivax or P. ovale relapsing malaria)
Common side effects
Key clinical trials
- An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria (PHASE3)
- Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria (PHASE3)
- Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria (PHASE3)
- Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matched-Placebo for Primaquine CI brief — competitive landscape report
- Matched-Placebo for Primaquine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Matched-Placebo for Primaquine
What is Matched-Placebo for Primaquine?
How does Matched-Placebo for Primaquine work?
What is Matched-Placebo for Primaquine used for?
Who makes Matched-Placebo for Primaquine?
What development phase is Matched-Placebo for Primaquine in?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Placebo control arm in clinical trials of primaquine for malaria (likely P. vivax or P. ovale relapsing malaria)
- Compare: Matched-Placebo for Primaquine vs similar drugs
- Pricing: Matched-Placebo for Primaquine cost, discount & access